13796-06-0

Upstream product

• 67-56-1 methanol 
• 6628-86-0 5-chloro-2-nitrobenzaldehyde 
• 149-73-5 trimethyl orthoformate 

Downstream Products

• 86813-46-9 1-(3-Formyl-4-nitrophenyl)piperazine hydrochloride 
• 158726-94-4 5-morpholino-2-nitrobenzaldehyde dimethyl acetal 
• 155626-37-2 5-(4-hydroxypiperidino)-2-nitrobenzaldehyde dimethylacetal 
• 130344-70-6 (3-dimethoxymethyl-4-nitro-phenyl)-phenyl-methanone 
• 548798-20-5 2-(dimethoxymethyl)-1-nitro-4-phenoxy-benzene 
• 1184030-26-9 (3-dimethoxymethyl-4-nitro-phenyl)-morpholin-4-yl-phenyl-acetonitrile 
• 20423-24-9 2-amino-5-(dimethylamino)benzaldehyde 
• 1071778-66-9 N,N-dimethyl-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-6-quinolinamine 
• 7187-62-4 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-quinolinium 
• 548798-17-0 3-(dimethoxymethyl)-N,N-dimethyl-4-nitrobenzenamine 
• 1184181-24-5 3-(3-dimethoxymethyl-4-nitro-phenylsulfanyl)-phenylamine 
• 548798-20-5 2-(dimethoxymethyl)-1-nitro-4-phenoxy-benzene 
• 1184171-20-7 3-(3-dimethoxymethyl-4-nitrophenoxy)-benzonitrile 
• 119198-32-2 6-<4-(3,4-dimethoxybenzoyl)-1-piperazinyl>-1H,3H-quinazoline-2,4-dione hydrochloride 

Relevant academic research and scientific papers

New synthesis of pyrvinium that inhibits the β-catenin/Tcf4 pathway

A new and converged route is described for synthesis of pyrvinium, an anthelmintic and antitumor agent. This method uses easily obtained materials and simple and practical reactions, including the key Friedlaender condensation, to form the quinoline ring. The final product is generated through eight steps, with 23% yield and 96.6% purity (HPLC). This synthetic pyrvinium effectively inhibits β-catenin/Tcf4 driven TOP-luciferase activity, with an IC50 value 50 of 0.54 ± 0.06 μM.

Radiolabelled MMP selective compounds

The invention is directed to radiolabelled MMP selective compounds, a processes for the preparation thereof, and uses thereof. The derivatives of the invention have formula (I) wherein Y represents O, CH2, (CH2)2, S, NH, o

NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)

The present invention is directed to novel 2-amino-3, 4-dihydro-quinazoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of P-secretase, also known as n-site cleaving enzyme and BACE.

NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)

The present invention is directed to novel 2-amino-3,4-dihydro-quinazoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer’s disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE.

2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF B-SECRETASE (BACE)

The present invention is directed to novel 2-amino-3,4-dihydro-quinazoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibi

Studies on new platelet aggregation inhibitors 1. Synthesis of 7-nitro-3,4-dihydroquinoline-2(1H)-one derivatives

A series of 6-cyclic aliphatic amino-7-nitro-3,4-dihydroquinoline-2(1H)-ones were prepared and tested for platelet aggregation inhibitory effect, cardiotonic activity and chronotropic activity. These compounds appeared to show selective inhibitory activity against platelet aggregation. Among them, 6-(4-ethoxycarbonylpiperidino)-7-nitro-3,4-dihydroquinoline-2(1H)-one (22f) showed the most potent inhibitory activity and high selectivity. A divergent synthetic route to 6-cyclic aliphatic amino-7-nitro-3,4-dihydroquinoline-2(1H)-one derivatives has also been investigated.

Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives, compositions and use

The present invention relates to novel positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives having positive inotropic and lusitropic properties which are useful in the treatment of warm-blooded animals suffering from Congestive Heart Failure. Pharmaceutical compositions containing said compounds as an active ingredient. Methods of preparing said compounds and pharmaceutical compositions.